mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years
mRNA-1083 demonstrated durable antibody responses against influenza and SARS-CoV-2 for 6 months with a favorable safety profile.
Asset / Drug
Drug and asset intelligence for Influenza with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Vaccine
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.